Plasminogen associates with phosphatidylserine-exposing platelets and contributes to thrombus lysis under flow

Blood

Volumn 125, Issue 16, 2015, Pages 2568-2578

  Whyte, Claire S ^a   Swieringa, Frauke ^b   Mastenbroek, Tom G ^b   Lionikiene, Ausra S ^a   Lancé, Marcus D ^b   Van Der Meijden, Paola E J ^b   Heemskerk, Johan W M ^b   Mutch, Nicola J ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CONVULXIN; DUAL SPECIFICITY PHOSPHATASE 2; FIBRIN; FIBRINOGEN; HIRUDIN; PHOSPHATIDYLSERINE; PLASMINOGEN; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; FIBRINOLYTIC AGENT; GLYCYL-PROLYL-ARGINYL-PROLINE; HEMOSTATIC AGENT; HIRUDIN DERIVATIVE; LECTIN; OLIGOPEPTIDE; PLASMIN; PROTEIN BINDING; SNAKE VENOM; THROMBIN; TYROSINE;

ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FIBRINOLYSIS; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; SHEAR RATE; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; THROMBUS; ANALOGS AND DERIVATIVES; DRUG EFFECTS; FLOW KINETICS; METABOLISM; SHEAR STRENGTH; THROMBOCYTE; THROMBOSIS;

BLOOD PLATELETS; CROTALID VENOMS; FIBRIN; FIBRINOLYSIN; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; FLOW CYTOMETRY; HEMOSTATICS; HIRUDINS; LECTINS, C-TYPE; MICROSCOPY, CONFOCAL; OLIGOPEPTIDES; PHOSPHATIDYLSERINES; PROTEIN BINDING; RHEOLOGY; SHEAR STRENGTH; THROMBIN; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR; TYROSINE; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84927720843     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-09-599480     Document Type: Article

References (67)

1. Heemskerk JW, Mattheij NJ, Cosemans JM. Platelet-based coagulation: different populations, different functions. J Thromb Haemost. 2013;11(1):2-16.
2. Stalker TJ, Traxler EA, Wu J, et al. Hierarchical organization in the hemostatic response and its relationship to the platelet-signaling network. Blood. 2013;121(10):1875-1885.
3. Munnix IC, Kuijpers MJ, Auger J, et al. Segregation of platelet aggregatory and procoagulant microdomains in thrombus formation: regulation by transient integrin activation. Arterioscler Thromb Vasc Biol. 2007;27(11):2484-2490.
4. Berny MA, Munnix IC, Auger JM, et al. Spatial distribution of factor Xa, thrombin, and fibrin(ogen) on thrombi at venous shear. PLoS ONE. 2010;5(4):e10415.
5. Bevers EM, Comfurius P, Zwaal RF. Platelet procoagulant activity: physiological significance and mechanisms of exposure. Blood Rev. 1991;5(3):146-154.
6. Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost. 2002;88(2):186-193.
7. Cosemans JM, Schols SE, Stefanini L, et al. Key role of glycoprotein Ib/V/IX and von Willebrand factor in platelet activation-dependent fibrin formation at low shear flow. Blood. 2011;117(2):651-660.
8. Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost. 2005;3(10):2185-2192.
9. Dale GL, Friese P, Batar P, et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature. 2002;415(6868):175-179.
10. Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL. Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood. 2000;95(5):1694-1702.
11. Szasz R, Dale GL. Thrombospondin and fibrinogen bind serotonin-derivatized proteins on COAT-platelets. Blood. 2002;100(8):2827-2831.
12. Robbie LA, Booth NA, Croll AM, Bennett B. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis. Thromb Haemost. 1993;70(2):301-306.
13. Fay WP, Eitzman DT, Shapiro AD, Madison EL, Ginsburg D. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms. Blood. 1994;83(2):351-356.
14. Levi M, Biemond BJ, van Zonneveld AJ, ten Cate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation. 1992;85(1):305-312.
15. Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol. 1988;70(3):327-333.
16. Maynard DM, Heijnen HF, Horne MK, White JG, Gahl WA. Proteomic analysis of platelet alpha-granules using mass spectrometry. J Thromb Haemost. 2007;5(9):1945-1955.
17. Veljkovic DK, Rivard GE, Diamandis M, Blavignac J, Cramer-Bordé EM, Hayward CP. Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation. Blood. 2009;113(7):1535-1542.
18. Coppinger JA, Cagney G, Toomey S, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood. 2004;103(6):2096-2104.
19. Baeten KM, Richard MC, Kanse SM, Mutch NJ, Degen JL, Booth NA. Activation of single-chain urokinase-type plasminogen activator by platelet-associated plasminogen: a mechanism for stimulation of fibrinolysis by platelets. J Thromb Haemost. 2010;8(6):1313-1322.
20. Plow EF, Doeuvre L, Das R. So many plasminogen receptors: why? J Biomed Biotechnol. 2012;2012:1-6.
21. Miles LA, Plow EF. Binding and activation of plasminogen on the platelet surface. J Biol Chem. 1985;260(7):4303-4311.
22. Adelman B, Michelson AD, Loscalzo J, Greenberg J, Handin RI. Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood. 1985;65(1):32-40.
23. Dejouvencel T, Doeuvre L, Lacroix R, et al. Fibrinolytic cross-talk: a new mechanism for plasmin formation. Blood. 2010;115(10):2048-2056.
24. Stricker RB, Wong D, Shiu DT, Reyes PT, Shuman MA. Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregation. Blood. 1986;68(1):275-280.
25. Ouimet H, Freedman JE, Loscalzo J. Kinetics and mechanism of platelet-surface plasminogen activation by tissue-type plasminogen activator. Biochemistry. 1994;33(10):2970-2976.
26. Loscalzo J, Pasche B, Ouimet H, Freedman JE. Platelets and plasminogen activation. Thromb Haemost. 1995;74(1):291-293.
27. Plow EF, Freaney DE, Plescia J, Miles LA. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol. 1986;103(6 pt 1):2411-2420.
28. Hall SW, Humphries JE, Gonias SL. Inhibition of cell surface receptor-bound plasmin by alpha 2-antiplasmin and alpha 2-macroglobulin. J Biol Chem. 1991;266(19):12329-12336.
29. Robbie LA, Young SP, Bennett B, Booth NA. Thrombi formed in a Chandler loop mimic human arterial thrombi in structure and RAI-1 content and distribution. Thromb Haemost. 1997;77(3):510-515.
30. Varjú I, Sótonyi P, Machovich R, et al. Hindered dissolution of fibrin formed under mechanical stress. J Thromb Haemost. 2011;9(5):979-986.
31. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med. 2002;8(10):1175-1181.
32. Mutch NJ, Moore NR, Wang E, Booth NA. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. J Thromb Haemost. 2003;1(9):2000-2007.
33. van der Meijden PE, Schoenwaelder SM, Feijge MA, et al. Dual P2Y 12 receptor signaling in thrombin-stimulated platelets - involvement of phosphoinositide 3-kinase beta but not gamma isoform in Ca2+ mobilization and procoagulant activity. FEBS J. 2008;275(2):371-385.
34. Magwenzi SG, Ajjan RA, Standeven KF, Parapia LA, Naseem KM. Factor XIII supports platelet activation and enhances thrombus formation by matrix proteins under flow conditions. J Thromb Haemost. 2011;9(4):820-833.
35. Neeves KB, Maloney SF, Fong KP, et al. Microfluidic focal thrombosis model for measuring murine platelet deposition and stability: PAR4 signaling enhances shear-resistance of platelet aggregates. J Thromb Haemost. 2008;6(12):2193-2201.
36. Van Kruchten R, Cosemans JM, Heemskerk JW. Measurement of whole blood thrombus formation using parallel-plate flow chambers - a practical guide. Platelets. 2012;23(3):229-242.
37. Lancé MD, Ninivaggi M, Schols SE, et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. Vox Sang. 2012;103(1):25-34.
38. Munnix IC, Strehl A, Kuijpers MJ, et al. The glycoprotein VI-phospholipase Cgamma2 signaling pathway controls thrombus formation induced by collagen and tissue factor in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2005;25(12):2673-2678.
39. Siljander P, Farndale RW, Feijge MA, et al. Platelet adhesion enhances the glycoprotein VI-dependent procoagulant response: involvement of p38 MAP kinase and calpain. Arterioscler Thromb Vasc Biol. 2001;21(4):618-627.
40. Heemskerk JW, Feijge MA, Henneman L, Rosing J, Hemker HC. The Ca2+-mobilizing potency of alpha-thrombin and thrombin-receptor-activating peptide on human platelets - concentration and time effects of thrombin-induced Ca2+ signaling. Eur J Biochem. 1997;249(2):547-555.
41. Booth NA, MacGregor IR, Hunter NR, Bennett B. Plasminogen activator inhibitor from human endothelial cells. Purification and partial characterization. Eur J Biochem. 1987;165(3):595-600.
42. de Witt SM, Swieringa F, Cavill R, et al. Identification of platelet function defects by multiparameter assessment of thrombus formation. Nat Commun. 2014;5:4257.
43. Gallino A, Haeberli A, Hess T, Mombelli G, Straub PW. Fibrin formation and platelet aggregation in patients with acute myocardial infarction: effects of intravenous and subcutaneous low-dose heparin. Am Heart J. 1986;112(2):285-290.
44. Collet JP, Park D, Lesty C, et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol. 2000;20(5):1354-1361.
45. Gabriel DA, Muga K, Boothroyd EM. The effect of fibrin structure on fibrinolysis. J Biol Chem. 1992;267(34):24259-24263.
46. Thelwell C, Longstaff C. The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1. J Thromb Haemost. 2007;5(4):804-811.
47. Suenson E, Lützen O, Thorsen S. Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis. Eur J Biochem. 1984;140(3):513-522.
48. Tran-Thang C, Kruithof EK, Bachmann F. Tissue-type plasminogen activator increases the binding of glu-plasminogen to clots. J Clin Invest. 1984;74(6):2009-2016.
49. Harpel PC, Chang TS, Verderber E. Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I. J Biol Chem. 1985;260(7):4432-4440.
50. Bok RA, Mangel WF. Quantitative characterization of the binding of plasminogen to intact fibrin clots, lysine-sepharose, and fibrin cleaved by plasmin. Biochemistry. 1985;24(13):3279-3286.
51. Tran-Thang C, Kruithof EK, Atkinson J, Bachmann F. High-affinity binding sites for human Glu-plasminogen unveiled by limited plasmic degradation of human fibrin. Eur J Biochem. 1986;160(3):599-604.
52. Fleury V, Anglés-Cano E. Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochemistry. 1991;30(30):7630-7638.
53. Collet JP, Montalescot G, Lesty C, Weisel JW. A structural and dynamic investigation of the facilitating effect of glycoprotein IIb/IIIa inhibitors in dissolving platelet-rich clots. Circ Res. 2002;90(4):428-434.
54. Abaeva AA, Canault M, Kotova YN, et al. Procoagulant platelets form an α-granule protein-covered "cap" on their surface that promotes their attachment to aggregates. J Biol Chem. 2013;288(41):29621-29632.
55. Mitchell JL, Lionikiene AS, Fraser SR, Whyte CS, Booth NA, Mutch NJ. Functional factor XIII-A is exposed on the stimulated platelet surface. Blood. 2014;124(26):3982-3990.
56. Kulkarni S, Jackson SP. Platelet factor XIII and calpain negatively regulate integrin alphaIIbbeta3 adhesive function and thrombus growth. J Biol Chem. 2004;279(29):30697-30706.
57. Miles LA, Ginsberg MH, White JG, Plow EF. Plasminogen interacts with human platelets through two distinct mechanisms. J Clin Invest. 1986;77(6):2001-2009.
58. Soslau G, Class R, Morgan DA, et al. Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib. J Biol Chem. 2001;276(24):21173-21183.
59. Plow EF, Collen D. The presence and release of alpha 2-antiplasmin from human platelets. Blood. 1981;58(6):1069-1074.
60. Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest. 1984;74(4):1465-1472.
61. Kruithof EK, Tran-Thang C, Bachmann F. Studies on the release of a plasminogen activator inhibitor by human platelets. Thromb Haemost. 1986;55(2):201-205.
62. Sprengers ED, Akkerman JW, Jansen BG. Blood platelet plasminogen activator inhibitor: two different pools of endothelial cell type plasminogen activator inhibitor in human blood. Thromb Haemost. 1986;55(3):325-329.
63. Fay WP, Owen WG. Platelet plasminogen activator inhibitor: purification and characterization of interaction with plasminogen activators and activated protein C. Biochemistry. 1989;28(14):5773-5778.
64. Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem. 1978;84(2):573-578.
65. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem. 1982;257(6):2912-2919.
66. Stalker TJ, Welsh JD, Tomaiuolo M, et al. A systems approach to hemostasis: 3. Thrombus consolidation regulates intrathrombus solute transport and local thrombin activity. Blood. 2014;124(11):1824-1831.
67. Wang X, Palasubramaniam J, Gkanatsas Y, et al. Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets. Circ Res. 2014;114(7):1083-1093.